{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:11:37Z","timestamp":1790266297139,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K12244"],"award-info":[{"award-number":["25K12244"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmorwd.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Real World Data and Digital Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.esmorw.2026.100734","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T21:25:11Z","timestamp":1782854711000},"page":"100734","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world safety and efficacy of enzalutamide versus darolutamide in nonmetastatic castration-resistant prostate cancer: a multicenter retrospective study"],"prefix":"10.1016","volume":"13","author":[{"given":"K.","family":"Ishimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8284-9582","authenticated-orcid":false,"given":"N.","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Tabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Yoneyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Oishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Togashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Okita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Horiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Noro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ohyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmorw.2026.100734_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmorw.2026.100734_bib2","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00345-013-1157-5","article-title":"The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy","volume":"32","author":"Kluth","year":"2014","journal-title":"World J Urol"},{"key":"10.1016\/j.esmorw.2026.100734_bib3","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/iju.15535","article-title":"Significance of androgen-deprivation therapy for intermediate- and high-risk prostate cancer treated with high-dose radiotherapy: a literature review","volume":"31","author":"Aizawa","year":"2024","journal-title":"Int J Urol"},{"key":"10.1016\/j.esmorw.2026.100734_bib4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/iju.15647","article-title":"Triplet therapy for metastatic castration-sensitive prostate cancer: rationale and clinical evidence","volume":"32","author":"Suzuki","year":"2025","journal-title":"Int J Urol"},{"key":"10.1016\/j.esmorw.2026.100734_bib5","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1038\/onc.2013.206","article-title":"Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches","volume":"32","author":"Karantanos","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.esmorw.2026.100734_bib6","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2005.01.529","article-title":"Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer","volume":"23","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmorw.2026.100734_bib7","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","article-title":"Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer","volume":"382","author":"Sternberg","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmorw.2026.100734_bib8","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa2001342","article-title":"Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide","volume":"383","author":"Fizazi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmorw.2026.100734_bib9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.prnil.2023.12.002","article-title":"Real-world effects of novel androgen receptor axis-targeted agents on oncological outcomes in non-metastatic castration-resistant prostate cancer: a multi-institutional retrospective study","volume":"12","author":"Fujita","year":"2024","journal-title":"Prostate Int"},{"key":"10.1016\/j.esmorw.2026.100734_bib10","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1007\/s10147-025-02827-w","article-title":"Real-world trends in the use and outcomes of novel androgen receptor signaling inhibitor therapy in patients with non-metastatic castration-resistant prostate cancer: a multicenter retrospective study","volume":"30","author":"Yoneyama","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.esmorw.2026.100734_bib11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bju.13123","article-title":"Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer","volume":"117","author":"Schalken","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.esmorw.2026.100734_bib12","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s11523-020-00779-x","article-title":"Darolutamide: a review in non-metastatic castration-resistant prostate cancer","volume":"15","author":"Scott","year":"2020","journal-title":"Target Oncol"},{"key":"10.1016\/j.esmorw.2026.100734_bib13","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1007\/s10147-025-02881-4","article-title":"Cross-resistance among novel androgen receptor signaling inhibitors in non-metastatic castration-resistant prostate cancer","volume":"30","author":"Oishi","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.esmorw.2026.100734_bib14","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1111\/iju.70235","article-title":"Androgen receptor signaling inhibitors in non-metastatic castration-resistant prostate cancer in Japan: the ARASHI Study","volume":"32","author":"Suzuki","year":"2025","journal-title":"Int J Urol"},{"key":"10.1016\/j.esmorw.2026.100734_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.29783","article-title":"Androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer","volume":"7","author":"George","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.esmorw.2026.100734_bib16","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmorw.2026.100734_bib17","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.juro.2008.01.099","article-title":"Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time","volume":"179","author":"Arlen","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.esmorw.2026.100734_bib18","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.esmorw.2026.100734_bib19","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.urolonc.2020.03.022","article-title":"Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: a systematic review and network meta-analysis","volume":"38","author":"Kumar","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.esmorw.2026.100734_bib20","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1007\/s10147-020-01777-9","article-title":"Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis","volume":"25","author":"Mori","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.esmorw.2026.100734_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/srep12007","article-title":"Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies","volume":"5","author":"Moilanen","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.esmorw.2026.100734_bib22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1200\/JCO.2018.36.6_suppl.345","article-title":"Blood-brain barrier penetration of [14C]darolutamide compared with [14C]enzalutamide in rats using whole body autoradiography","volume":"36","author":"Zurth","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmorw.2026.100734_bib23","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/00498254.2020.1723038","article-title":"Absorption, distribution, metabolism and excretion of darolutamide (a novel non-steroidal androgen receptor antagonist) in rats","volume":"50","author":"Taavitsainen","year":"2020","journal-title":"Xenobiotica"},{"key":"10.1016\/j.esmorw.2026.100734_bib24","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/j.clgc.2019.05.016","article-title":"Drug\u2013drug interactions in prostate cancer treatment","volume":"18","author":"Hebenstreit","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.esmorw.2026.100734_bib25","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.euf.2017.01.010","article-title":"Safety and antitumour activity of ODM-201 (BAY-1841788) in castration-resistant, CYP17 inhibitor-na\u00efve prostate cancer: results from extended follow-up of the ARADES trial","volume":"3","author":"Fizazi","year":"2017","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.esmorw.2026.100734_bib26","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40264-024-01415-7","article-title":"Enzalutamide: understanding and managing drug interactions to improve patient safety and drug efficacy","volume":"47","author":"Lennep","year":"2024","journal-title":"Drug Saf"},{"key":"10.1016\/j.esmorw.2026.100734_bib27","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s40262-015-0283-1","article-title":"Pharmacokinetic drug interaction studies with enzalutamide","volume":"54","author":"Gibbons","year":"2015","journal-title":"Clin Pharmacokinet"}],"container-title":["ESMO Real World Data and Digital Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820126000536?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820126000536?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:42:07Z","timestamp":1790264527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949820126000536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":27,"alternative-id":["S2949820126000536"],"URL":"https:\/\/doi.org\/10.1016\/j.esmorw.2026.100734","relation":{},"ISSN":["2949-8201"],"issn-type":[{"value":"2949-8201","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world safety and efficacy of enzalutamide versus darolutamide in nonmetastatic castration-resistant prostate cancer: a multicenter retrospective study","name":"articletitle","label":"Article Title"},{"value":"ESMO Real World Data and Digital Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmorw.2026.100734","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100734"}}